Bausch + Lomb (B + L) is more than one of the oldest eye care companies in the industry. It is also one of the broadest, with portfolios in contact lenses, consumer eye products, cataract surgery, intraocular lenses, retina surgery, and a wide range of ophthalmic pharmaceutical products.
The company also has busy pipeline working on novel drug delivery systems and the first glaucoma medication to exploit nitric oxide as a mechanism to expand the trabecular meshwork and enhance outflow.
“Focusing on innovation, moving innovation forward, is what drives us all every day,” said Tracy M. Valorie, MBA, senior vice president, general manager, B + L Pharmaceutical and Valeant Women’s Health. “Fifty percent of the entire Valeant organization revenues are anchored against B+ L. That sets the tone of the importance of eye care to the organization and of the importance of B + L to Valeant. B + L has a heritage of 164 years of eye care.”
Valorie discussed the current B + L portfolio and future directions for an Industry Spotlight during the New Horizons Forum, held in conjunction with the 2017 Glaucoma 360 meeting.
Valeant, which acquired B + L in 2013, named Joseph Papa chairman and CEO in May 2016. The company derives 30% of revenues from branded pharmaceuticals, she noted, and 20% from diversified product, such as anti-inflammatories, anti-infectives, neurologics, and other categories.